Type of Spiritual Experience
A description of the experience
Palivizumab (brand name Synagis ) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV. In two Phase III clinical trials in the pediatric population, palivizumab reduced the risk of hospitalization due to RSV infection by 55% and 45%. Palivizumab is dosed once a month via intramuscular (IM) injection, to be administered throughout the duration of the RSV season
Palivizumab targets the fusion protein of RSV inhibiting its entry into the cell and thereby preventing infection.
On Feb, 11, 2016: 7,295 people reported to have side effects when taking Synagis. Among them, 1 people (0.01%) has Hallucination.
Age of people who have Hallucination when taking Synagis :
On Jan, 17, 2016: 7,295 people reported to have side effects when taking Synagis. Among them, 285 people (3.91%) have Death.
Time on Synagis when people have Death :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Gender of people who have Death when taking Synagis :
Age of people who have Death when taking Synagis :
Top conditions involved for these people :
- Premature baby (19 people, 6.67%)
- Respiratory syncytial virus infection (19 people, 6.67%)